Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Chin J Cancer Res
2014 Aug 01;264:410-7. doi: 10.3978/j.issn.1000-9604.2014.08.01.
Show Gene links
Show Anatomy links
TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression.
Liu Q
,
Yang P
,
Tu K
,
Zhang H
,
Zheng X
,
Yao Y
,
Liu Q
.
???displayArticle.abstract???
OBJECTIVE: Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a nuclear proliferation-related protein that plays a critical role in the formation of mitotic spindle. High expression of TPX2 has been observed in several types of tumors. However, the role of TPX2 in hepatocellular carcinoma (HCC) remains unclear. Our study aimed to investigate the effect of TPX2 on HCC cell invasion.
METHODS: The immortalized normal human liver cell line L02 and six HCC cell lines including SMMC-7721, BEL-7402, Huh-7, HepG2, Hep3B and SKHep1 were subjected to qRT-PCR and western blot for TPX2 mRNA and protein, respectively. Furthermore, TPX2 small interfering RNA (siRNA) was used to knock down TPX2 expression in SMMC-7721 and HepG2 cells. Cell proliferation and invasion were determined by MTT and transwell assays. Otherwise, expression of p-AKT, MMP2 and MMP9 were evaluated by western blot in SMMC-7721 cells.
RESULTS: The expression of TPX2 in HCC cell lines was markedly higher than that in normal human liver cell line. TPX2 knockdown using a specific TPX2-siRNA reduced the number of invaded cells and inhibited cell proliferation in SMMC-7721 and HepG2 cells. Furthermore, TPX2 knockdown resulted in inactivation of AKT signaling and down-regulation of MMP2 and MMP9 expression in SMMC-7721 cells.
CONCLUSIONS: Our study identified that TPX2 might contribute to tumor cell invasion through activating AKT signaling and subsequently increasing MMP2 and MMP9 in HCC.
Aguirre-Portolés,
Tpx2 controls spindle integrity, genome stability, and tumor development.
2012,
Pubmed
Alazawi,
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.
2010,
Pubmed
Bruix,
Management of hepatocellular carcinoma: an update.
2011,
Pubmed
Cáceres-Gorriti,
RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.
2014,
Pubmed
Chang,
The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer.
2012,
Pubmed
Chien,
Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.
2010,
Pubmed
El-Serag,
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.
2003,
Pubmed
Ferlay,
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
2010,
Pubmed
Gao,
Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9.
2013,
Pubmed
Gruss,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells.
2002,
Pubmed
,
Xenbase
Heidebrecht,
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M.
1997,
Pubmed
Jemal,
Global cancer statistics.
2011,
Pubmed
Kessenbrock,
Matrix metalloproteinases: regulators of the tumor microenvironment.
2010,
Pubmed
Kufer,
Human TPX2 is required for targeting Aurora-A kinase to the spindle.
2002,
Pubmed
,
Xenbase
Leng,
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
2003,
Pubmed
Li,
Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients.
2013,
Pubmed
Neumayer,
TPX2: of spindle assembly, DNA damage response, and cancer.
2014,
Pubmed
Satow,
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
2010,
Pubmed
Scaggiante,
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.
2014,
Pubmed
Shigeishi,
Expression of TPX2 in salivary gland carcinomas.
2009,
Pubmed
Sieber,
Genomic stability and tumorigenesis.
2005,
Pubmed
Venook,
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
2010,
Pubmed
Wang,
MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma.
2014,
Pubmed
Wang,
Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines.
2013,
Pubmed
Wei,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
2013,
Pubmed
Welker,
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.
2013,
Pubmed
Yan,
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.
2013,
Pubmed
Zheng,
Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling.
2013,
Pubmed
